

Date: October 7, 2022

To,
EudraCT team
European Medicines Agency

Subject: EudraCT results document

Dear EudraCT team

I, William Schilling, am the co-principal investigators of the “Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)”. I would like to respond to the "prematurely ended" notice in the EudraCT database.

The COPCOV trial unfortunately never recruited participants in the European Union due to difficulties related to Sponsorship and regulatory concerns in other territories resulting from a fraudulent publication reporting safety concerns, which were subsequently retracted. Additionally, the COPCOV trial enrolment in the UK was closed out as of early 2021. COPCOV completed the study's recruitment in March 2022, with 4,646 participants enrolled from several sites across the world including Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Niger, Pakistan, Thailand, the UK and Zambia. The study has finished.

Although there were delays in obtaining shipping approvals and import licenses, we are currently processing samples and anticipate having the study results by the end of the year. These will be publicly posted.

Please do not hesitate to be in contact should you have any queries and if you would like us to do anything else.

Yours faithfully,



(Dr. William Schilling)

Research Physician

Mahidol-Oxford Tropical Medicine Research Unit
Faculty of Tropical Medicine, Mahidol University, Thailand

